LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK, Aug. 8,
2019 /CNW Telbec/ - Prometic Life Sciences
Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), wishes to correct
an error in its press release entitled "Prometic to report its
second quarter financial results and hold a conference call" issued
on August 7th, 2019.
Prometic's conference call will be held at 8:30 a.m. (EDT),
rather than 11:00 a.m. (EDT) on
Tuesday, August 13th, 2019.
The telephone numbers to access the conference call are
1-888-231-8191 and 647-427-7450. An audio replay of the call will
be available as of Tuesday, August
13th, 2019 at 11:30 a.m.
(EDT).The numbers to access the audio replay are
416-849-0833 and 1-855-859-2056 using the following password:
3058704.
A live audio webcast of the conference call will be available
via:
https://event.on24.com/wcc/r/2064037/B88200AF0A89D874A738E49894DA07B6
About Prometic
Prometic (www.prometic.com) is an innovative biopharmaceutical
corporation with a broad pipeline of small molecule therapeutics
under development to treat unmet needs in patients with liver,
respiratory and kidney disease, including rare diseases. Prometic's
differentiated research involves the study of two
G-protein-coupled-receptors, GPR40 and GPR84. These drug candidates
have a dual mode-of-action as agonists ("stimulators") of GPR40 and
antagonists ("inhibitors") of GPR84. Our lead drug candidate,
PBI-4050, is expected to enter Phase 3 clinical studies for the
treatment of Alström Syndrome. A second drug candidate, PBI-4547,
is expected to enter Phase 1 clinical studies in 2019. Prometic
also has leveraged its experience in bioseparation technologies to
isolate and purify biopharmaceuticals from human plasma. The lead
plasma-derived therapeutic product is Ryplazim™ (plasminogen) which
the Company expects to file a BLA with the US FDA seeking approval
to treat patients with congenital plasminogen deficiency. The
Corporation also operates a contract development and manufacturing
operation in the United Kingdom,
deriving revenue through sales of affinity chromatography media.
Prometic has active business operations in Canada, the United
States and the United
Kingdom.
Forward Looking Statements
This presentation contains forward-looking statements about
Prometic's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited
to, Prometic's ability to develop, manufacture, and successfully
commercialize value-added pharmaceutical products, the availability
of funds and resources to pursue R&D projects, the successful
and timely completion of clinical studies, the ability of Prometic
to take advantage of business opportunities in the pharmaceutical
industry, uncertainties related to the regulatory process and
general changes in economic conditions. You will find a more
detailed assessment of the risks that could cause actual events or
results to materially differ from our current expectations in the
Annual Information Form for the year ended December 31, 2018, under the heading "Risk
Factors". As a result, we cannot guarantee that any forward-looking
statement will materialize. We assume no obligation to update any
forward-looking statement even if new information becomes
available, as a result of future events or for any other reason,
unless required by applicable securities laws and regulations. All
amounts are in Canadian dollars unless indicated otherwise.
SOURCE ProMetic Life Sciences Inc.